Outcome of 5-Azacitidine and Decitabine Treatment in Elderly Patients with Myelodysplastic Syndrome

被引：0
|
作者：
Nam, Seung-Hyun [1 ]
Lim, Taekyu [1 ]
Kim, Bong-Seog [1 ]
机构：
[1] VHS Med Ctr, Seoul, South Korea
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4959.4959
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4959
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Duong, Vu H.
    Lin, Karen
    Reljic, Tea
    Kumar, Ambuj
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06): : 711 - 715
  • [22] 5-AZACITIDINE TREATMENT RESTORES RESPONSE TO EPOETIN THERAPY IN HIGH RISK MYELODYSPLASTIC (MDS) PATIENTS
    Volpe, M.
    Volpe, A.
    HAEMATOLOGICA, 2012, 97 : 588 - 589
  • [23] Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients
    Kulasekararaj, Austin G.
    Mohamedali, Azim M.
    Smith, Alexander E.
    Lea, Nicholas C.
    Kizilors, Aytug
    Abdallah, Atiyeh
    Nasser, Erik E.
    Mian, Syed A.
    Yiu, Richard
    Gaken, Joop
    Pomplun, Sabine
    Jiang, Jie
    Gaymes, Terry J.
    Pasipanodya, Patience
    Hayden, Janet
    Ireland, Robin M.
    Lim, ZiYi
    Ho, Aloysius Y.
    Marsh, Judith C. W.
    Mufti, Ghulam J.
    BLOOD, 2010, 116 (21) : 61 - 61
  • [24] USE OF 5-AZACITIDINE IN ELDERLY AND FRAGILES PATIENTS DIAGNOSED WITH LAM. IS IT A TREATMENT OPTION?
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Ramo Alejandro, Vazquez
    Maqueda Cristina, Fernandez
    Martin Sonia, Herrero
    Perez Dolores, Subira
    Albiz Blanca, Pinedo
    HAEMATOLOGICA, 2016, 101 : 331 - 331
  • [25] Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
    Kobayashi, Yukio
    Munakata, Wataru
    Ogura, Michinori
    Uchida, Toshiki
    Taniwaki, Masafumi
    Kobayashi, Tsutomu
    Shimada, Fumika
    Yonemura, Masataka
    Matsuoka, Fumiko
    Tajima, Takeshi
    Yakushijin, Kimikazu
    Minami, Hironobu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (01) : 83 - 91
  • [26] Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
    Yukio Kobayashi
    Wataru Munakata
    Michinori Ogura
    Toshiki Uchida
    Masafumi Taniwaki
    Tsutomu Kobayashi
    Fumika Shimada
    Masataka Yonemura
    Fumiko Matsuoka
    Takeshi Tajima
    Kimikazu Yakushijin
    Hironobu Minami
    International Journal of Hematology, 2018, 107 : 83 - 91
  • [27] Comparison of the IPSS and IPSS-R in Predicting Survival and Response of Myelodysplastic Syndrome Patients to 5-Azacitidine
    Shapiro, Roman M.
    Lazo-Langner, Alejandro
    BLOOD, 2016, 128 (22)
  • [28] Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine
    Stefania Infante, Maria
    Munoz, Carolina
    Heras, Cecilia
    Angeles Foncillas, Maria
    Gonzalez, Isabel
    Lucea, Irene
    Echavarria, Eva
    Aramendi, Teresa
    Angel Hernandez, Jose
    EUROPEAN JOURNAL OF DERMATOLOGY, 2015, 25 (06) : 622 - 623
  • [29] 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
    Gurion, Ronit
    Vidal, Liat
    Gafter-Gvili, Anat
    BeInik, Yulia
    Yeshurun, Moshe
    Raanani, Pia
    Shpilberg, Ofer
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 303 - 310
  • [30] Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine
    María Stefania Infante
    Carolina Muñoz
    Cecilia Heras
    María Angeles Foncillas
    Isabel González
    Irene Lucea
    Eva Echavarria
    Teresa Aramendi
    José Angel Hernández
    European Journal of Dermatology, 2015, 25 : 622 - 623
12345